INBX Inhibrx Biosciences, Inc.

NASDAQ
$97.93

Inhibrx Biosciences, Inc. (INBX) Insider Activity

What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.

30D 90D 6M 1Y
Insider signal In line Selling ran in line with INBX's own trailing one-year pace, with 0% of sale value under a prearranged plan.
Cluster activity 3 buyers in the last 30 days 3 buyers in the last 90 days 1 seller in the last 90 days
Insiders buying
3
13 transactions
Insiders selling
2
8 transactions
Purchases
$5.0M
47,500 shares
Sales
$11.6M
352,500 shares
Net activity
-$6.6M
purchases less sales

How much of that selling was preplanned? 0% planned / 100% discretionary

10b5-1 plan sales $0 0 transactions · 0 shares
Discretionary sales $11.6M 8 transactions · 352,500 shares

Largest single sale: $10.0M.

Where they traded

Buy Sell Dot area is proportional to transaction value.

Last open-market purchase: September 28, 2026 , by Lappe Mark .

Recent open-market activity

Date Insider Role Action Shares Price Value Held after
Lappe Mark 2 fills Chief Executive Officer Buy 4,500 $100.76 $453.4K 740,548
Lappe Mark 2 fills Chief Executive Officer Buy 5,500 $99.16 $545.4K 736,048
Kayyem Jon Faiz Director Buy 5,000 $100.00 $500.0K 434,360
MANHARD KIMBERLY Director Sell 500 $105.05 $52.5K 7,500 −6.3% of holding
MANHARD KIMBERLY Director Sell 500 $110.26 $55.1K 8,000 −5.9% of holding
MANHARD KIMBERLY Director Sell 500 $111.78 $55.9K 8,500 −5.6% of holding
MANHARD KIMBERLY Director Sell 500 $115.80 $57.9K 9,000 −5.3% of holding
Lappe Mark 6 fills Chief Executive Officer Buy 25,000 $105.82 $2.6M 730,548
Kayyem Jon Faiz Director Buy 5,000 $113.52 $567.6K 424,360
FORSYTH DOUGLAS Director Buy 2,500 $114.65 $286.6K 227,064
MANHARD KIMBERLY Director Sell 500 $115.14 $57.6K 9,500 −5% of holding
3 fills Sell 350,000 $32.25 $11.3M 1,267,823 −21.6% of holding

Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.